ArticleBiomarker research2019
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1.
Article in Biomarker research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02724696 (French National Observatory of Patients With Thymic Epithelial Tumor), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
French National Observatory of Patients With Thymic Epithelial Tumor
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Design of new drugs for medullary thyroid carcinoma.Frontiers in oncology · 2022Pooled it
- Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.Cancer immunology, immunotherapy : CII · 2026Review
- Molecular Landscape of Resected Thymomas: Insights from Mutational Profiling.Diagnostics (Basel, Switzerland) · 2026Article
- Prognostic and predictive biomarkers in thymic epithelial tumors: beyond traditional staging: a narrative review.Mediastinum (Hong Kong, China) · 2026Review
- Pathobiology of thymic epithelial tumours and the treatment strategy based on immuno-oncological characteristics: a narrative review.Mediastinum (Hong Kong, China) · 2026Review
- Immune Checkpoint Therapy for Thymic Carcinoma.Cancers · 2025Review
- Programmed death-ligand 1 expression in surgically resected thymomas.Updates in surgery · 2025Article
- Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.Cancer research communications · 2025Article
- Identification of the immune-associated enhancer RNA SATB1-AS1 as a novel biomarker for thymic cancer prognosis.PloS one · 2025Article
- Article
- Pan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors.Cancer cell international · 2024Article
- Review
- PD-L1 Expression in Neoplastic and Immune Cells of Thymic Epithelial Tumors: Correlations with Disease Characteristics and HDAC Expression.Biomedicines · 2024Article
- Immune checkpoint inhibitor myocarditis in thymic epithelial tumors: a case report and literature review.Translational cancer research · 2024Article
- Combining serum inflammatory markers and clinical factors to predict survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors.Therapeutic advances in medical oncology · 2024Article
- Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors.Exploration of targeted anti-tumor therapy · 2024Review
- Review
- Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.Molecular cancer · 2023Review
- Article
- Thymic tumours and their special features.European respiratory review : an official journal of the European Respiratory Society · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 13 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunotherapy is currently under investigation in B3 Thymoma (TB3) and Thymic Carcinoma (TC). PD-L1 expression has been evaluated on a limited number of patients with selected antibodies. We aimed to analyze cohort of TB3 and TC with a panel of antibodies to assess the prevalence of PD-L1 expression, its prognostic value and to set up a reproducible test.
methodsWe retrospectively studied 103 patients samples of FFPE histologically confirmed TB3 (
resultsTB3 epithelial cells had a higher and more diffuse expression of PD-L1 than TC regardless the antibodies tested (
conclusionFrequent PD-L1 expression, particularly in TB3, paves the way for immunotherapy in TET (Thymic Epithelial Tumor). Otherwise, we have set up three reproducible LDT (laboratory-developed test) for four PD-L1 antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.